Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com 855-907-3286
Clinical.Trials@bms.com


First line of the email MUST contain the NCT# and Site #.


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Back

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Recruiting

Open to: ALL

Age: 18.0 - 65.0

Bodmin Brighton Ashton Under Lyne Oxford Chertsey Birmingham London Glasgow

Medical Conditions

Schizophrenia

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily \[BID\]) in subjects with schizophrenia.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Mar 2022 Mar 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID

Intervention Arm Group : Drug: KarXT;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Local Institution - 707
    Bodmin
    Cornwall
    PL31 2QN
  • Local Institution - 705
    Brighton
    East Sussex
    BN1 9RY
  • Local Institution - 706
    Ashton Under Lyne
    Lancashire
    OL6 7SR
  • Local Institution - 708
    Oxford
    Oxfordshire
    OX3 7JX
  • Local Institution - 702
    Chertsey
    Surrey
    KT16 9AU
  • Local Institution - 703
    Birmingham
    West Midlands
    B4 6NH
  • Local Institution - 701
    London
    Greater London
    SE5 8AF
  • Local Institution - 704
    Glasgow
    G51 4TF

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com 855-907-3286
Clinical.Trials@bms.com


First line of the email MUST contain the NCT# and Site #.



The study is sponsored by Karuna Therapeutics



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05304767
Last updated 08 May 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top